Article Sidebar

PDF (Tiếng Việt)
Published: 2021-06-09
Abstract Views: 291
Views PDF (Tiếng Việt): 538
DOI: https://doi.org/10.52852/tcncyh.v140i4.126
Issue
Vol. 140 No. 4 (2021)
Section
Các bài báo
How to Cite
Khánh, N. N. ., & Dũng, V. C. . (2021). Outcomes of infantile onset pompe disease patients at the national childrent’s hospital. Journal of Medical Research, 140(4), 20-25. https://doi.org/10.52852/tcncyh.v140i4.126

Outcomes of infantile onset pompe disease patients at the national childrent’s hospital

Nguyễn Ngọc Khánh, Vũ Chí Dũng

Main Article Content

Abstract

Pompe disease is a rare inherited disease result from GAA gene mutations. Enzyme replacement therapy (ERT) has been effective in Infant Onset Pompe Disease (IOPD). To evaluate outcomes of ERT in IOPD patients, we performed a case series study on 31 IOPD patients from 2015 at the National Hospital of Pediatrics. The average age of children diagnosed and received ERT were 4.2 and 4.9 months, respectively. Male/ female rate was 15/16. The average duration of ERT was 20 months. 100% of patients survived after 1 year of management; 77.4% of patients reached an average age of 34 months. 24/25 patients improved heart function after 1 year of management: left ventricular mass index (LVMI) decreased from 183 g /m2 to 70 g/m2. 66.7% of patients ambulated independently with the current mean age of 3 years. 4/31 patients required respiratory support (tracheostomy / mechanical ventilation) and require oral tube feeding. In conclusion, ERT for IOPD pediatric patients has been significantly effective, especially in early diagnosis.

Article Details

Keywords

infantile onset pompe disease.

References

1.Taverna S, Cammarata G, Colomba P, et al. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging. 2020;12(15):15856-15874. doi:10.18632/aging.103794.
2. Mccall AL, Salemi J, Bhanap P, Strickland LM, Elmallah MK. The impact of Pompe disease on smooth muscle: a review. J Smooth Muscle Res. 2018;54:100-118. doi:10.1540/jsmr.54.100.
3. Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive overview. Ann Transl Med. 2019;7(13). doi:10.21037/atm.2019.04.13.
4.Sun A. Lysosomal storage disease overview. Ann Transl Med. 2018;6(24). doi:10.21037/atm.2018.11.39.
5.Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantile-onset Pompe disease. Cochrane Database Syst Rev. 2017;11:CD011539. doi:10.1002/14651858.CD011539.pub2.
6. Kim M-S, Song A, Im M, et al. Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center. Korean J Pediatr. 2019;62(6):224-234. doi:10.3345/kjp.2018.06968.
7. Fukuhara Y, Fuji N, Yamazaki N, et al. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Rep. 2017;14:3-9. doi:10.1016/j.ymgmr.2017.10.009.
8. Ngiwsara L, Wattanasirichaigoon D, Tim-Aroon T, et al. Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand. BMC Med Genet. 2019;20. doi:10.1186/s12881-019-0878-8.
9. Al-Hassnan ZN, Khalifa OA, Bubshait DK, et al. The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients. Mol Genet Metab Rep. 2018;15:50-54. doi:10.1016/j.ymgmr.2018.02.001.
10. Capelle CI van, Poelman E, Frohn-Mulder IM, et al. Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase. Int J Cardiol. 2018;269:104-110. doi:10.1016/j.ijcard.2018.07.091.
11. Parini R, De Lorenzo P, Dardis A, et al. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy. Orphanet J Rare Dis. 2018;13. doi:10.1186/s13023-018-0771-0.